INBUILD-ON (NCT03820726) was an open-label extension trial investigating long-term safety and efficacy of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. It was a pleasure to talk with Dr. Eric Matteson (Mayo Clinic College of Medicine and Science, Rochester, MN, USA) to discuss the aims, eligibility criteria and the most common adverse events reported in INBUILD-ON.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON.’ (Abstract number: 0186) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What did the INBUILD study teach us about the efficacy and safety of nintedanib on patients with progressive fibrosing ILDs?
- What are the aims and eligibility criteria of the INBUILD-ON study?
- What were the most common adverse events of nintedanib reported in INBUILD-ON?
- What were the conclusions regarding future use of nintedanib in this patient population?
Disclosures: Eric Matteson discloses consulting for Boehringer Ingelheim and Alvotech Inc; receiving honoraria from Practice Point Communications and Boehringer Ingelheim; participating on speaker’s bureaus for Practice Point Communications; and other financial support from UpToDate and Horizon Therapeutics.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
